About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

Our lead investigational product candidate, AFREZZA®
(pronounced uh-FREZZ-uh)
is a first-in-class, ultra rapid-acting mealtime insulin therapy being developed to improve glycemic control in adults with Type 1 and Type 2 diabetes mellitus. More >

Spotlight

Researchers announced the first successful clinical trial using the artificial pancreas in conjunction with ultra-rapid acting inhaled insulin (AFREZZA®). To read the release and watch the video, More >

News & Events

   
Apr 07, 2014 MannKind Updates Status of New Drug Application for AFREZZA(R) More >
Apr 01, 2014 FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's... More >
Feb 19, 2014 MannKind Corporation to Present at Upcoming Conferences More >